Fleckenstein G, Osmers R, Puchta J
Department of Gynecology and Obstetrics, University of Göttingen, Germany.
Med Oncol. 1998 Dec;15(4):212-21. doi: 10.1007/BF02787203.
Monoclonal antibodies have progressed from the laboratory to the clinic. Although recognised in diagnosis there are still problems as far as their therapeutic use is concerned. This review looks at the history, principles of active specific immunotherapy, clinical experience with monoclonal antibodies in therapy of solid tumours, in particular the development of new bispecific monoclonal antibodies, and trials in ovarian, breast and colorectal cancer. Immunoconjugates, linked with radionuclides and cytotoxic drugs, indicate future developments. Conditions for successful therapy, especially with adjuvants in patients with small tumour residues, are also described.
单克隆抗体已从实验室走向临床。尽管在诊断方面得到了认可，但就其治疗用途而言仍存在问题。本文综述了主动特异性免疫疗法的历史、原理、单克隆抗体治疗实体瘤的临床经验，尤其是新型双特异性单克隆抗体的研发，以及在卵巢癌、乳腺癌和结直肠癌方面的试验。与放射性核素和细胞毒性药物相连的免疫缀合物预示着未来的发展方向。文中还描述了成功治疗的条件，特别是在小肿瘤残留患者中使用佐剂的情况。
